The SQUEEZE project addresses how biomarkers can be used to optimize disease modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis (RA).

Welcome to the Squeeze Project

The SQUEEZE consortium comprehensively addressed how biomarkers can be used to optimize disease modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis (RA). RA is a chronic immune-mediated disease with enormous health-related quality of life and socioeconomic impact. Through nine dedicated work packages SQUEEZE integrates to validate clinical, laboratory, molecular, digital and behavioural biomarkers to enable the recognition of patients with high likelihood of response to treatment and the selection of the drug with highest chance of benefit for an individual patient; and as such improve efficacy and safety of existing therapies (by squeezing the most out of existing drugs) in synergy with other EU-wide activities.

13 PARTNERS

10 COUNTRIES

€ 8 602 316,25

5 years

OUR CONSORTIUM

We are a team of leading academic centres with a first-class record in translational and clinical research, together with patients and small and medium sized enterprises (SMEs)

SQUEEZE project

We aim to have a real impact on life of people with rheumatoid arthritis

PAST EVENTS